Whilst no therapies have been developed specifically for treating speech and language conditions associated with single gene variants to date, there are evidence based treatments for available for certain communication disorders. At present, a child's individual speech pathology clinician will assess the child and develop a personally tailored intervention plan.

*Please note that all treatment options need to be discussed with your speech pathologist to ensure that they are right for you/ your child*

To date, The Nuffield Dyspraxia Programme (NDP) and Rapid Syllable Transition Treatment (ReST) have the highest level of evidence when treating childhood apraxia of speech.

Professor Tricia McCabe and The University of Sydney are currently completing clinical trials on the efficacy of apraxia of speech treatments. For more information about these trials, please follow the link below.

For more information about the above treatments mentioned, please see below;

    • Morgan, A.T., Murray, E & Liégeois (2018). Interventions for childhood apraxia of speech. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD006278.pub3.
    • Murray, E., McCabe, P., & Ballard, K.J. (2015). A Randomized Controlled Trial for Children With Childhood Apraxia of Speech Comparing Rapid Syllable Transition Treatment and the Nuffield Dyspraxia Programme-Third Edition. Journal of Speech, Language and Hearing Research, 58(3), 669-686.                                                 
    • University of Sydney. (2018). Rapid Syllable Transition Treatment
    • The Nuffield Dyspraxia Programme (NDP).                              

There are currently a number of evidence based approaches for treatment of dysarthria. Below you will find journal articles discussing the most up to date evidence based treatments.

Please find below information describing some of the evidence based treatments.

Proudly in partnership with